Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Pfizer logo
PfizerPFE
0.1×0.0×
Amgen logo
AmgenAMGN
0×0.0×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
0.7×-0.4×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
1.6×-0.1×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
6.9×+4.4×

Other financials

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0×0.0×
Current ratio5.7×-38.5×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

cash and equivalents/total current liabilities=1.1×

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's cash ratio?
Viking Therapeutics (VKTX) reported cash ratio of 1.1× in Q1 2026.
How has Viking Therapeutics's cash ratio changed year-over-year?
Viking Therapeutics's cash ratio decreased by 42.7% year-over-year, from 1.9× to 1.1×.
What is the long-term trend for Viking Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Viking Therapeutics's cash ratio has grown at a -2.1% compound annual growth rate (CAGR), from 2.4× to 2.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.